Abivax S.A.
AAVXF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $2 | $4 | $7 | $2 |
| % Growth | -49.7% | -41% | 202.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2 | $4 | $7 | $2 |
| % Margin | 100% | 100% | 100% | 83.2% |
| R&D Expenses | $78 | $82 | $65 | $71 |
| G&A Expenses | $16 | $15 | $18 | $16 |
| SG&A Expenses | $18 | $17 | $22 | $22 |
| Sales & Mktg Exp. | $2 | $2 | $4 | $6 |
| Other Operating Expenses | -$0 | -$2 | -$0 | $0 |
| Operating Expenses | $96 | $97 | $87 | $96 |
| Operating Income | -$94 | -$93 | -$80 | -$90 |
| % Margin | -4,645.3% | -2,321.2% | -1,178.9% | -4,016.8% |
| Other Income/Exp. Net | -$7 | -$2 | -$4 | -$8 |
| Pre-Tax Income | -$101 | -$95 | -$82 | -$96 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$101 | -$95 | -$82 | -$96 |
| % Margin | -4,996.7% | -2,361.6% | -1,203% | -4,266.7% |
| EPS | -1.59 | -1.5 | -1.3 | -1.91 |
| % Growth | -6% | -15.4% | 31.9% | – |
| EPS Diluted | -1.59 | -1.5 | -1.3 | -1.91 |
| Weighted Avg Shares Out | 63 | 63 | 63 | 50 |
| Weighted Avg Shares Out Dil | 63 | 63 | 63 | 50 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $5 | $0 |
| Interest Expense | $7 | $1 | $8 | $6 |
| Depreciation & Amortization | $0 | $1 | $0 | $0 |
| EBITDA | -$94 | -$92 | -$80 | -$90 |
| % Margin | -4,640.3% | -2,298% | -1,176.3% | -4,011% |